Clinical Trial Update: A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial of faricimab in choroidal neovascularization due to age-related macular degeneration has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Faricimab (faricimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Choroidal Neovascularization | Phase 2 | Status: COMPLETED | Results posted: 2020-10-09